Vaccine adjuvants

Perspectives in Vaccinology

Volumn 1, Issue 1, 2011, Pages 89-113

  Garçon, Nathalie ^a   Leroux Roels, Geert ^a   Cheng, Wen Fang ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; AS 01; AS 03; AS 04; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FLUVAL; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIPOSOME; LIVE VACCINE; MELANOMA ANTIGEN 3; MIFAMURTIDE; MONTANIDE ISA 51; PANFLU; PNEUMOCOCCUS VACCINE; QS 21; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VIROSOME; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN PURIFICATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; EMULSION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VACCINE PRODUCTION;

EID: 83455162495     PISSN: 22107622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pervac.2011.05.004     Document Type: Article

References (21)

1. Banzhoff A., Gasparini R., Laghi-Pasini F., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009, 4:e4384.
2. Brichard V.G., Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine 2007, 25(Suppl. 2):B61-B71.
3. Cooper C.L., Davis H.L., Morris M.L., et al. CpG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24:693-701.
4. Didierlaurent A.M., Morel S., Lockman L., et al. AS04, an aluminum salt- and TLR-4 agonist-based Adjuvant System, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
5. Kester K.E., Cummings J.F., Ofori-Anyinam O., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200. 337-246.
6. Kong N.C.T., Beran J., Kee S.A., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005, 68:2298-2303.
7. Leroux-Roels I., Borkowski A., Vanwolleghem T., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
8. Leroux-Roels I., Bernhard R., Gérard P., et al. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3:e1665.
9. Morel S., Didierlaurent A., Bourguignon P., et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
10. Newman M.J., Wu J.Y., Gardner B.H., et al. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 1997, 15:1001-1007.
11. Paavonen J., Naud P., Salmeron J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
12. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19:2673-2680.
13. Roman F., Vaman T., Gerlach B., et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28:1740-1745.
14. Seubert A., Monaci E., Pizza M., et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008, 180:5402-5412.
15. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
16. Giannini S.L., Hanon E., Moris P., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
17. Lambrecht B.N., Kool M., Willart M.A.M., et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21:23-29.
18. Leroux-Roels G. Unmet needs in modern vaccinology. Adjuvants to improve the immune response. Vaccine 2010, 28S:C25-C36.
19. Ott A., Van Nest G. Development of vaccine adjuvants: A historical perspective. Vaccine Adjuvants and Delivery Systems 2007, 1-31. John Wiley & Sons, New Jersey. M. Singh (Ed.).
20. Vogel F.R., Hem S.L. Immunologic adjuvants. Vaccines 2008, 59-71. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
21. Wilson-Welder J.H., Torres M.P., Kipper M.J., et al. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 2009, 98:1278-1316.